// App-Quantinova.ai

5115 : Pre-clinical development of next generation inhibitors of the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase as cancer immunotherapies

Researchers

Presenter

  • Alan Wise

Principal Investigators

  • Barry E. McGuinness

  • Sarah C. Trewick

  • Thomas J. Brown

  • Phillip M. Cowley

Medical Centers

  • IOMET Pharma, Edinburgh, United Kingdom.

Locations

  • United Kingdom

Companies

  • IOmet Pharma Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Indoleamine 2,3-dioxygenase 1

  • Kynurenine

  • L-tryptophan

Drug/Treatment

  • tryptophan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved